Our Technologies

Read about our available technologies and get in touch with our team




Clear all filters

A model score calculated from levels of circulating plasma proteins for the diagnosis, prognosis, and treatment optimisation of Pulmonary Arterial Hypertension.
miRNA biomarkers to identify patients with pulmonary hypertension (PH), and sub-classify patients with pulmonary arterial hypertension (PAH) and chronic thromembolic PH (CTEPH)
A nanoparticle drug platform that can deliver small molecule drugs over a sustained period in a stable, low-toxic manner.
Innovative transducer designs and image reconstruction algorithms, enabling effective 3D/4D imaging in clinical practice
These novel compounds could be used in the treatment of antibiotic resistant bacterial infections and demonstrate that inhibitors of NorA efflux can prevent the emergence of further resistant strains.
Plastic waste upcycling into high-performance battery anodes for the next-generation of fast-charging and low-cost sodium-ion batteries (NIBs).
A filter matrix for use in the removal of haemoglobin, haem and free iron from the blood to combat poor patient outcomes resulting from haemolysis.
An immunotherapy platform capable of enhancing the anti-tumour efficacy of invariant natural killer T cells (iNKT).

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Licensing and IP performance 2019/20

Inventions disclosed

Imperial inventors submitted 250 invention disclosures to our IPC team during the year

Active licences

Imperial College London's licensing portfolio comprises 244 licences

Patents filed

Imperial filed 137 patents (including PCT applications) during the year

Patent portfolio

Imperial's patent portfolio reached 331 patents during the year

Upcoming Events

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Latest News

Accelerated development of a potential treatment for cystic fibrosis

Accelerated development of a potential treatment for cystic fibrosis

The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more

Natural Killer – licensing a cell therapy

Natural Killer – licensing a cell therapy

Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more